

Regimen Reference Order – CNS – etoposide (oral)

ARIA: CNS – [etoposide (oral)]

Planned Course: Once daily for 3 weeks, then 1 week off (1 cycle = 28 days) until disease progression or unacceptable toxicity

Indication for Use: High Grade Glioma, Recurrent

Proceed with treatment if:

ANC equal to or greater than $1.5 \times 10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$

❖ Contact Physician if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Treatment Regimen – CNS – etoposide (oral)

Drug	Dose	CCMB Administration Guideline
ondansetron	4 mg	Orally once daily 30 minutes prior to etoposide on Days 1 to 21 , followed by 7 days off (Self-administered at home)
etoposide	50 mg	Orally once daily on Days 1 to 21 , followed by 7 days off Take on an empty stomach. Swallow whole (Self-administered at home)
etoposide (VePesid®) available dosage strength: 50 mg capsule Classification: Cytotoxic, Hazardous		

REQUIRED MONITORING

All Cycles

- CBC, serum creatinine, urea, electrolytes, liver enzymes, LDH, total bilirubin, uric acid and albumin as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

INSTRUCTIONS FOR PATIENT

- etoposide has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Reinforce applicable safe handling precautions of medications, blood and body fluids while on etoposide

ADDITIONAL INFORMATION

- All oral agents as part of this regimen (etoposide, ondansetron and metoclopramide) will be dispensed by CancerCare Manitoba Pharmacy